Hou Hongqiao, Jiang Bowen, Zhu Aiqing, Hou Junjun, Qu Zhe, Liu Ruping, Li Aiqun
Emergency Surgery Department, Yantai Affiliate Hospital of Binzhou Medical University, Yantai, Shandong, China.
Department of Dermatology and Venereology, Yantai Affiliate Hospital of Binzhou Medical University, Yantai, Shandong, China.
Front Pharmacol. 2025 Jan 16;15:1514602. doi: 10.3389/fphar.2024.1514602. eCollection 2024.
This study was designed to investigate the protective effect and mechanism of Sufentanil on acute lung injury in septic mice based on network pharmacology and animal experiments, and to provide new ideas for clinical treatment. To this end, a protein-protein interaction (PPI) network for common targets was first constructed with Swiss Target Prediction Database, GeneCards Database, Draw Venn Diagram Software, STRING 11.5 Database, Cytoscape 3.10.0 Software and Metascape Database, and then key targets were subject to enrichment analysis by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) to obtain the key targets of Sufentanil for the treatment of pulmonary sepsis, and then verified by animal experiments. A sepsis model was constructed by cecal ligation and puncture (CLP) in this study, and lung tissues and bronchoalveolar lavage fluid (BALF) were taken from each group of mice. The morphological changes of lung tissues and apoptosis were observed by HE and TUNEL staining, the content of inflammatory factors in the lung tissues was detected by ELISA, and the expression of proteins, such as p-JAK2 and p-STAT3, was detected in the lung tissues by Western blotting. According to the results of network pharmacology, a total of 40 common targets of were screened out for Sufentanil and pulmonary sepsis, and GO enrichment analysis involved 1,483 biological processes (BPs), 84 cellular components (CCs) and 125 molecular functions (MFs); KEGG enrichment analysis identified 137 signaling pathways with p < 0.05 such as JAK-STAT. According to the results of animal experiments, compared with the control group, mice in the model group had severe lung tissue injury and elevated expression of relevant inflammatory factors in lung tissue. Compared with the model group, CLP + Sufentanil group showed reduced pathomorphologic lesions, lower expression of inflammatory factors and apoptosis level, as well as lower expression of p-JAK2 and p-STAT3 proteins in lung tissue. The results of animal experiments were consistent with network pharmacology. In summary, Sufentanil may improve lung injury in septic mice by inhibiting the JAK2-STAT3 signaling pathway, which provides a basis for research on the mechanism of Sufentanil on pulmonary sepsis and clinical treatment.
本研究旨在基于网络药理学和动物实验探讨舒芬太尼对脓毒症小鼠急性肺损伤的保护作用及机制,为临床治疗提供新思路。为此,首先利用瑞士靶点预测数据库、基因卡片数据库、绘制韦恩图软件、STRING 11.5数据库、Cytoscape 3.10.0软件和Metascape数据库构建常见靶点的蛋白质-蛋白质相互作用(PPI)网络,然后通过基因本体论(GO)和京都基因与基因组百科全书(KEGG)对关键靶点进行富集分析,以获得舒芬太尼治疗肺部脓毒症的关键靶点,随后通过动物实验进行验证。本研究采用盲肠结扎穿刺(CLP)构建脓毒症模型,并采集每组小鼠的肺组织和支气管肺泡灌洗液(BALF)。通过苏木精-伊红(HE)和TUNEL染色观察肺组织的形态学变化和细胞凋亡情况,采用酶联免疫吸附测定(ELISA)检测肺组织中炎症因子的含量,通过蛋白质免疫印迹法检测肺组织中p-JAK2和p-STAT3等蛋白的表达。根据网络药理学结果,共筛选出舒芬太尼与肺部脓毒症的40个共同靶点,GO富集分析涉及1483个生物学过程(BP)、84个细胞成分(CC)和125个分子功能(MF);KEGG富集分析确定了137条p<0.05的信号通路如JAK-STAT。根据动物实验结果,与对照组相比,模型组小鼠肺组织损伤严重,肺组织中相关炎症因子表达升高。与模型组相比,CLP+舒芬太尼组肺组织病理形态学损伤减轻,炎症因子表达和凋亡水平降低,肺组织中p-JAK2和p-STAT3蛋白表达也降低。动物实验结果与网络药理学结果一致。综上所述,舒芬太尼可能通过抑制JAK2-STAT3信号通路改善脓毒症小鼠的肺损伤,为舒芬太尼治疗肺部脓毒症的机制研究及临床治疗提供了依据。